There has never been a dispute about this: Innovation is the lifeblood of healthcare. Literally. And the discoveries made are more than value drivers for the companies behind them; they can be life savers to millions needing better and more effective healthcare solutions. While that need is straightforward enough, history shows that, in most cases, it’s not an easy deliverable.
A scrutinizing FDA, the capital-intensive nature of discovery, and the lengthy timelines to earn marketing approvals often limit a company’s ability to turn ambition into products and, better still, revenues. The excellent news, however, is that some companies, including Florida-based BioStem Technologies Inc. (OTC: BSEM), are overcoming these formidable challenges. And the results from navigating these hurdles are spectacular.
BioStem announced an outstanding first quarter. Revenue reached $41.9 million, nearly 71X higher than roughly $0.6 million for last year’s comparable quarter. Growth accelerated by the continued successful commercial acceptance into the private office setting of AmnioWrap2. Also notable is that the gross margin on those sales reached 95% compared to 82% in the first quarter of 2023. That certainly sends revenues faster toward our bottom line, which is expected to increase from the distribution agreement with Venture Medical. Most importantly, from an investor’s perspective, on a GAAP basis, BSEM reported being net income positive for the first time in its history and converted from a net shareholders’ deficit position into a net positive equity position.
Growth Is No Coincidence
That growth is no coincidence. It results from BioStem taking the meticulous steps required to satisfy regulators, meet a compelling need with effective products, and successfully target open doors of opportunity to generate potential ROI windfalls from commercialization approvals. Despite its small-cap classification, BioStem appears exceptionally well-positioned to capitalize on and maximize value from products that target specialized indications in the regenerative medicine and MedTech sector, a status they’ve earned.
BioStem’s growth can be attributed to sticking to its mission of discovering, developing, and producing the most effective regenerative medicine products in the world. That intent is noticed. Recent milestones and successfully navigating strategic initiatives have led to BioStem earning the prioritization of the examination of the patent for one of its key value drivers, BioRetain technology, by the U.S. Patent Office, a pivotal asset in the production of BioStem’s best-in-class placental tissue allografts.
Multiple Products Target High Dollar Markets
Patent approvals protect development, market position, and the rewards of commercialization. However, they aren’t the primary value drivers. Tangible assets and their potentials take on that role, which BioStem assigns from its list of clinical programs that include VENDAJE™, VENDAJE™ AC, VENDAJE™ OPTIC, and AMNIOWRAP2, products that are processed at the company’s FDA-registered and AATB-accredited site in Pompano Beach, Florida. The company is not short on optimism related to the potential of these assets. The VENDAJE™ and AMNIOWRAP2 products have been described as best-in-class placental tissue allografts that are not just innovative—they are transformative.
BioStem is backing that claim. AmnioWrap2® posted what BioStem called Breakthrough Results in its Retrospective Wound Care Study in a June 2024 update. Results were compelling, even published in a peer-reviewed journal, which noted that BioStem’s products offer better overall treatment efficiency and greater efficiency in general wound closure. These results are timely.
Regenerative medicine, which harnesses the body’s natural healing abilities, is set to revolutionize healthcare, ushered in part by the global stem cell market projected to reach $18.4 billion by 2028. That puts BioStem in the right markets with the right assets at the right time, particularly regarding the growing interest and investment in stem cell research, which is in BioStem’s development wheelhouse from its focus on perinatal tissue allografts, particularly those derived from the human placenta.
Familiarity with that specialization helps position BioStem at the forefront of this growing and essential sector. That’s where the recent patent prioritization review adds value since BioStem’s proprietary BioRetain® processing method maintains growth factors and preserves tissue structure, a competitive advantage over existing products that would be strengthened upon patent approvals.
Pipeline and Project Potential Earn Major Price Target Increase
With the future looking bright, the progress at BioStem is also being appreciated. Zacks Small Cap Research models for shares to reach $23.25 within the next twelve months, roughly 127% higher than its current $10.20 on Monday. They support that lofty forecast by noting in its report an expectation for unprecedented revenue growth, resulting from BioStem doing the essential groundwork to solidify its position as a top clinical-stage MedTech company by leveraging cutting-edge technology to develop and commercialize advanced therapies that address critical healthcare needs.
Optimism is warranted. As noted, BioStem’s operational progress in 2023 has been nothing short of remarkable. These figures, accretive to valuation models, underscore BioStem’s ability to scale its operations efficiently while maintaining high profit margins. Additional value is assigned from acquiring assets from Auxocell Laboratories and the nationwide launch of AmnioWrap2 with Venture Medical LLC. These strategic initiatives have significantly expanded BioStem’s capabilities and market reach. The initiation of a clinical trial for DFU and the commercialization agreements for Avenova Allograft with NovaBay further highlight BioStem’s commitment to advancing its product pipeline and bringing additional innovative solutions to patients sooner rather than later.
BioStem’s exceptional growth rate reflects its adept navigation through the complex regulatory landscape and ability to capitalize on market opportunities. Recognizing the growth velocity led to Zacks Small Cap Research raising its price target for the third time over the past few months, highlighted by Zacks saying, “We reiterate our belief that BSEM is still underpriced even after its recent move higher and continues to represent a good opportunity at recent prices for investors to get in before what we believe will be a more aggressive move higher in the not-too-distant future.”
Market Numbers Support The Bullish Thesis
Reasons support that bullish presumption. In addition to excellent products, BioStem’s growth trajectory is supported by a highly experienced commercial team focused on monetizing two major markets: diabetic wound care and surgical wound care. The global wound care market, valued at $21.2 billion in 2022, is projected to reach $27.2 billion by 2027. The diabetic foot ulcer treatment market, valued at $4.44 billion in 2022, is expected to grow at a compound annual growth rate (CAGR) of 5.4% from 2022 to 2030. BioStem’s innovative solutions position it to significantly impact, and reap the potential spoils, from its solutions serving these markets.
Remember, BioStem Technologies Inc. is not just another MedTech company but a pioneering force in regenerative medicine. Furthermore, they are generating impressive financial headlines, capitalizing on strategic market initiatives, and advancing what may be one of the most innovative product pipelines in the space. The potentially better news is that BioStem has notable support, including value from collaboration with distinguished clients and partners, including the Center for Medicare Services (CMS) and the U.S. Department of Veterans Affairs (V.A.). Those relationships can do more than accelerate study timelines; they instill market credibility, a valuable inclusion in the resume of a company looking to penetrate the multibillion-dollar soft tissue repair market, which is expected to reach around $8.6 billion by 2030.
BioStem’s listing with the U.S. Department of Defense and Veterans’ Administration, along with achieving CMS reimbursement for Vendaje AC® and AmnioWrap2, could help the company tap into that potential. Keep in mind that those listings do more than create revenue streams; they also indicate the company’s strong market position, which is earned from achievements that validate the efficacy and importance of BioStem’s products. In other words, BioStem is hitting its operational stride on all fronts.
Milestones To Catalysts In 2024
While the sum of the parts mentioned is appealing, it would be remiss not to factor in a leadership team that brings focus and marketing vision. Leading BioStem forward into an ambitious 2024 are CEO Jason Matuszewski and Chief Operating Officer Andrew Van Vurst, who co-founded the company in 2014. Both are driven by a passion for regenerative medicine, which contributes to the company’s clear mission and understanding of how to take ideas and transform them into products that can save lives.
BioStem has also retained an experienced clinical research professional to lead its Diabetic Foot Ulcer (DFU) and Venous Leg Ulcer (VLU) trials. These trials are proactive measures to address potentially changing reimbursement requirements by Medicare Administrative Contractors. With the healthcare landscape constantly evolving, BioStem’s forward-thinking approach ensures it remains ahead of regulatory and market changes. From a company and investor perspective, that strategy can further steepen a revenue curve that is already trending decidedly higher.
Indeed, great things can come from smallcap companies. But keep in mind that while BioStem is “small”, it isn’t tiny. It currently holds a market cap of over $166 million with shares are priced at $10.20 yesterday. That makes BioStem nimble enough to move quickly toward opportunities and at the same time attract interest from institutional investors. Both are important for growth stocks. And with signs supporting the premise of this company shifting its growth pace into a higher gear, they can each contribute toward reaching the Zacks Small Cap Research price target that’s 127% higher from here.
Disclaimers: This presentation has been created by Hawk Point Media Group, Llc. (HPM) and is responsible for the production and distribution of this content. This presentation should be considered and explicitly regarded as sponsored content. Hawk Point Media Group, LLC. has been compensated up to five thousand dollars via wire transfer from Sideways Frequency Llc. to research, compile, produce, and create digital content as part of a more extensive digital marketing program. Accordingly, this content may be used and syndicated beyond the channels used by Hawk Point Media, Llc. This disclaimer and the link to the broader disclosures must be part of all reproductions. The compensation received by HPM creates a conflict of interest because the content presented may only provide a favorable viewpoint of the company featured. The contributors do NOT buy and sell securities before and after any article, report, or publication. HPM holds ZERO shares and has never owned stock in BioStem Technologies. The information in this video, article, and related newsletters is not intended to be, nor does it constitute, investment advice or recommendations. Hawk Point Media Group, Llc. strongly urges you to conduct a complete and independent investigation of the respective companies and consider all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. Never take opinions, articles presented, or content provided as the sole reason to invest in any featured company. Investors must always perform their own due diligence before investing in any publicly traded company and understand the risks involved, including losing their entire investment.
Media Contact
Company Name: Hawk Point Media
Contact Person: Editorial Dept.
Email: info@hawkpointmedia.com
Country: United States
Website: https://hawkpointmedia.com/